Daraxonrasib Doubles Pancreatic Cancer Survival in FDA Trial
On August 26, 2026, the FDA approved daraxonrasib (Rasonque) for metastatic pancreatic cancer. The RAS inhibitor doubled median survival to 13.2 month
Daraxonrasib Doubles Pancreatic Cancer Survival in FDA Trial Read More »
